BASELINE
Editor's Note: Patient Worthy is proud to share this article from our friends at the Courageous Parents Network. A parent often can sense when there has been a shift in…
Continue Reading
BASELINE
FDA Escalates Scrutiny of GLP‑1 Compounders as Industry Reports Key Clinical and Regulatory Updates
As reported by BioPharmaDive, he Food and Drug Administration (FDA) has intensified its oversight of companies marketing compounded GLP‑1 therapies, while Intellia Therapeutics, United Therapeutics, Merck & Co., and federal…
Continue Reading
FDA Escalates Scrutiny of GLP‑1 Compounders as Industry Reports Key Clinical and Regulatory Updates
Blood-Based circRNA Marker Shows Promise for Predicting Antidepressant Response
As reported on MedicalXpress, a new study published in Molecular Psychiatry suggests that a specific circular RNA found in blood, known as CDR1as, may help forecast how patients with major…
Continue Reading
Blood-Based circRNA Marker Shows Promise for Predicting Antidepressant Response
First Patient Dosed in Phase 3 CLARITY Trial Evaluating Solriamfetol for MDD With Excessive Daytime Sleepiness
As published in Sleep Review Magazine, Axsome Therapeutics has officially begun dosing patients in its Phase 3 CLARITY trial, a study designed to evaluate solriamfetol as a potential treatment for…
Continue Reading
First Patient Dosed in Phase 3 CLARITY Trial Evaluating Solriamfetol for MDD With Excessive Daytime Sleepiness
Life Impact of Pain – Pain Series Part 2 of 3
Click here to see Part 1 of of this 3 part pain series. If you suffer with chronic pain, you not only live with the unrelenting sensation of pain, but probably…
Continue Reading
Life Impact of Pain – Pain Series Part 2 of 3
Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer
AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Datroway (datopotamab deruxtecan) has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for use as an initial treatment in adults…
Continue Reading
Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer
After the Diagnosis: Self-Harming Thoughts and So Many Questions
After being diagnosed with a rare disease or any other chronic health condition (in my case I have dystonia) and learning it is not a temporary problem (or if you…
Continue Reading
After the Diagnosis: Self-Harming Thoughts and So Many Questions
FDA Advances Rivoceranib-Camrelizumab Combination: A Promising Breakthrough for First-Line Unresectable Hepatocellular Carcinoma Treatment
Elevar Therapeutics has achieved a significant regulatory milestone with the US Food and Drug Administration's acceptance of a resubmitted New Drug Application for rivoceranib in combination with camrelizumab as first-line…
Continue Reading
FDA Advances Rivoceranib-Camrelizumab Combination: A Promising Breakthrough for First-Line Unresectable Hepatocellular Carcinoma Treatment
Nutcracker Syndrome, May-Thurner Syndrome, and More: Tytina’s Journey to a Proper Diagnosis
Sharing My Stripes 🦓 This Rare Disease Month, I'm honored to share my journey living as someone with a rare disease and what Rare Disease Month means to me. This…
Continue Reading
Nutcracker Syndrome, May-Thurner Syndrome, and More: Tytina’s Journey to a Proper Diagnosis
Sleep, Sodium Intake, and Hypertension: New Initiative Highlights Critical Health Connection
A growing body of research shows that sleep quality, dietary sodium, and hypertension are more closely linked than once believed — and two major healthcare organizations are joining forces to…
Continue Reading
Sleep, Sodium Intake, and Hypertension: New Initiative Highlights Critical Health Connection
Caplyta Shows Strong Remission Gains in Phase III Depression Study
As reported by the European Pharmacy Review, a combination approach using Johnson & Johnson’s small‑molecule therapy Caplyta (lumateperone) alongside standard antidepressants continues to show promising results for adults with major…
Continue Reading
Caplyta Shows Strong Remission Gains in Phase III Depression Study
The Value of Living with Tremendous Challenges
If you got past the title without rolling your eyes or getting angry (I understand if you did either or both as you will see below), I hope you will…
Continue Reading
The Value of Living with Tremendous Challenges
FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy
The U.S. Food and Drug Administration (FDA) has approved Yartemlea (narsoplimab‑wuug), marking the first authorized therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA) in adults and children aged 2…
Continue Reading
FDA Approves First Treatment for Stem Cell Transplant–Associated Thrombotic Microangiopathy
Pediatric Palliative Care
Editor's Note: Patient Worthy is honored to bring you this article, originally written by Kelsey Stanczyk, and shared with us by our friends at the Courageous Parents Network. So much…
Continue Reading
Pediatric Palliative Care
Why Palliative Care Shouldn’t Wait: A Nurse and Mother’s Story
Editor's Note: Patient Worthy is proud to share this story from the Courageous Parents Network, originally written by Kelsey Stanczyk. When I first became a nurse, I worked in an…
Continue Reading
Why Palliative Care Shouldn’t Wait: A Nurse and Mother’s Story
Biohaven’s BHV‑7000 Falls Short in Midstage Depression Trial, Refocusing Pipeline Strategy
As reported on FierceBioTech, Biohaven closed out the holiday period with disappointing news: its investigational Kv7.2/7.3 potassium‑channel modulator, BHV‑7000, did not demonstrate efficacy in a phase 2 clinical trial for…
Continue Reading
Biohaven’s BHV‑7000 Falls Short in Midstage Depression Trial, Refocusing Pipeline Strategy
FDA Approves First At-Home Brain Stimulation Device for Depression
As reported by Forbes, the U.S. Food and Drug Administration has granted approval to Flow Neuroscience for the first prescription brain stimulation device designed for home use in treating major…
Continue Reading
FDA Approves First At-Home Brain Stimulation Device for Depression
Advanced Brain Scans, and Chinese Medicine, Show Promise for Personalized Depression Care
As reported on Science Daily, a recent clinical study suggests that a traditional Chinese herbal remedy may offer a unique advantage in treating major depressive disorder (MDD) while paving the…
Continue Reading
Advanced Brain Scans, and Chinese Medicine, Show Promise for Personalized Depression Care
It Was All a Dream
Editor's Note: Patient Worthy is honored to share Michelle Patidar's patient story, provided to us by our friends at Elephants & Tea. To see the article in its original format,…
Continue Reading
It Was All a Dream
From Cancer Treatment to Childhood Health: How Foresee’s Injectable Drug Addresses a Rare Pediatric Challenge
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet, according to FiercePharma.com, Foresee Pharmaceuticals…
Continue Reading
From Cancer Treatment to Childhood Health: How Foresee’s Injectable Drug Addresses a Rare Pediatric Challenge
CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials
CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic malignancies. Autoimmune Disease Progress In…
Continue Reading
CRISPR Therapeutics Shares Promising Updates on Zugo-cel in Autoimmune and Oncology Trials
FDA Approves Amneal’s Denosumab Biosimilars Boncresa and Oziltus
As reported on PharmaBiz, Amneal Pharmaceuticals, in collaboration with mAbxience, has received U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars: Boncresa (referencing Prolia) and Oziltus (referencing Xgeva).…
Continue Reading
FDA Approves Amneal’s Denosumab Biosimilars Boncresa and Oziltus
FDA Grants Full Approval to Rucaparib for BRCA-Mutated mCRPC
In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer (mCRPC) harboring deleterious BRCA mutations—either…
Continue Reading
FDA Grants Full Approval to Rucaparib for BRCA-Mutated mCRPC
What’s Missing From Many Surgeries? The Answer Might Be Your Nerves
There's a lot to consider when you’re facing tumor removal surgery. Think about mandible or jaw surgery, for example. Your face is part of every interaction you have, how you…
Continue Reading
What’s Missing From Many Surgeries? The Answer Might Be Your Nerves
Is Your Mental Diet Helping Or Hurting Your Health?
When we hear the word diet, most of us automatically think of food. But what about our thoughts? Let’s look at them in terms of consumption as well. According to…
Continue Reading
Is Your Mental Diet Helping Or Hurting Your Health?
- 1
- 2
- 3
- 4
- …
- 299
- Go to the next page
